Cytosystems

company

About

Cytosystems is a pathology company that develops non-invasive cancer diagnostic and stratification technologies for bladder cancer.

  • 1 - 10

Details

Last Funding Type
Angel
Industries
Biotechnology,Health Care,Health Diagnostics,Hospital,Medical,Medical Device
Founded date
Jan 1, 2006
Number Of Employee
1 - 10
Operating Status
Active

Cytosystems is a pathology company that develops non-invasive cancer diagnostic and stratification technologies for initially for the management of bladder cancer.

The company’s first product, BladderLight™, is an integrated and automated digital pathology solution using a big data systems approach for the diagnosis and monitoring of bladder cancer.

Cytosystems has developed two patent-pending technologies: a point of care cell collection device which optimizes analyte quality at point of patient care and the use of artificial intelligence pattern recognition software to interrogate and objectively classify individual urothelial cells as cancer positive or negative. This whole-cell approach can help with clinical decision making and provides a highly sensitive and specific test which achieves the challenging performance levels demanded of a non-invasive test by patients and clinicians.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
Cytosystems has raised a total of — in funding over 2 rounds. Their latest funding was raised on Jan 1, 2007 from a Angel round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 1, 2007 Angel 1 Aurora Private Equity Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Cytosystems is funded by 1 investors. Aurora Private Equity are the most recent investors.
Investor Name Lead Investor Funding Round
Aurora Private Equity Yes Angel